Investing in cannabis is 'a great hedge' for alcohol and drug companies, Tilray CEO says
Tilray CEO Brendan Kennedy shares his take on the future of medical and recreational marijuana with CNBC's Jim Cramer. Kennedy tells the "Mad Money" host that drug and alcohol makers should turn their focus to companies like his. Pharmaceutical companies have to start thinking about partnering with cannabis companies as a "hedge" against the burgeoning marijuana industry, Tilray TLRY CEO Brendan Kennedy told CNBC on Tuesday.